PDCD1 and neoplasm: Here, we tested AIPV and its subcombinations as a single-dose combination treatment prior to ICB and discovered that a simplified regimen combining a pan-tumor integrin-targeting antibody surrogate molecule with long half-life IL-2 and anti-PD-1, administered once, triggered remodeling of the TME, induction of rapid tumor cell death, and initiated T cell priming in tumor-draining lymph nodes.